Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd

Bayer Pharma Aktiengesellschaft (Bayer) brought an action against Generic Health Pty Ltd (Generic Health) in the Federal Court of Australia. Bayer alleged that Generic Health had infringed Bayer's patent for a pharmaceutical product. The crux of the dispute lay in the manufacturing process of the product, specifically the creation of tablets for subsequent testing. Bayer sought to inspect the manufacturing process but was denied access. Bayer then applied for leave to observe the manufacturing process.

The primary legal issue before the Court was whether Bayer should be granted leave to observe the manufacturing process at Generic Health's facility. Bayer argued that such inspection was necessary to gather experimental evidence to support its case. Generic Health, on the other hand, contended that allowing such observation would compromise its intellectual property and commercial interests. The Court had to balance Bayer's right to inspect against Generic Health's rights to protect its confidential information.

The Court held that Bayer's application for leave to observe the manufacturing process was an attempt to obtain evidence by circumventing the standard discovery process. It found that Bayer had not demonstrated that the evidence sought could not be obtained by other means. The Court also noted the significant burden that such an inspection would place on Generic Health, particularly regarding the protection of its intellectual property. Consequently, the Court dismissed Bayer's application for leave and ordered that Generic Health was to pay Bayer's costs of the interlocutory application.